Resumen de New Integrase Strand Transfer Inhibitor Approved To Treat HIV-1
* A new drug, Dolutegravir (Tivicay), has been approved to treat HIV-1 infection in both treatment-naïve patients and those who have received prior therapy against HIV infection.
* Possible serious adverse effects of the drug include hypersensitivity and abnormal liver function if the patient is coinfected with hepatitis B or hepatitis C.
